RapaLink-1
目录号 : KM5971 CAS No. : 1887095-82-0 纯度 : 97%

RapaLink-1 是第三代 mTOR 抑制剂,通过 linker 将雷帕霉素 (Rapamycin, ) 与二代 mTOR 抑制剂 MLN0128 结合。RapaLink-1 比雷帕霉素或 mTOR 抑制剂 (TORKi) 更有效,能有效地阻断癌源性的,激活的 mTOR 突变体。RapaLink-1 可以穿过血脑屏障。RapaLink-1 与 FKBP12 的结合导致持久抑制 mTORC1。RapaLink-1 通过促进自噬在抗磷脂综合征中发挥抗血栓作用。具有抗癌活性。

规格 价格 是否有货 数量
1mg
In-stock
5mg
In-stock
10mg
In-stock
25mg
In-stock
50mg 询价 In-stock
100mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin with MLN0128 (, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity.

IC50&Target

mTOR

 

体外研究

RapaLink-1 (0-200 nM; 3 days) shows U87MG cells growth inhibition.
RapaLink-1 (0-12.5 nM; 48 hours) arrests U87MG cells at G0/G1.
RapaLink-1 selectively inhibits p-RPS6 and p-4EBP1 at doses as low as 1.56 nM.
Rapalink-1 (100 nM; 24 to 96 hours) suppressed renal cell carcinoma (RCC) cell proliferation by inducing apoptosis and cell cycle arrest.
RapaLink-1 exploits the unique juxtaposition of two drug-binding pockets to create a bivalent interaction. RapaLink-1 overcomes resistance to existing first- and second-generation inhibitors.

Cell Proliferation Assay

Cell Line: U87MG cells
Concentration: 0-200 nM
Incubation Time: 3 days
Result: Showed growth inhibition.

Cell Cycle Analysis

Cell Line: U87MG cells
Concentration: 0-12.5 nM
Incubation Time: 48 hours
Result: Arrested cells at G0/G1.

Western Blot Analysis

Cell Line: U87MG cells
Concentration: 0.39-12.5 nM
Incubation Time: 3 hours
Result: Selectively inhibited p-RPS6 and p-4EBP1 at doses as low as 1.56 nM. The mTORC2 targets p-AKT, p-SGK1, and p-NDRG1, and the p-AKT target p-GSK3β was inhibited only at high doses.
体内研究

RapaLink-1 (i.p.; every 5 days for 25 days, then once a week for 11 week) shows potent anti-tumor efficacy.

Animal Model: BALB/ Cnu/nu mice bearing U87MG intracranial xenografts
Dosage: 1.5 mg/kg
Administration: I.p.; every 5 days for 25 days, then once a week for 11 week
Result: Led to initial regression and subsequent stabilization of tumor size.
分子式
C91N12O24H138
分子量
1784.14
CAS号
1887095-82-0
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 178 mg/mL (99.77 mM; Need ultrasonic and warming)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.5605 mL 2.8025 mL 5.6049 mL
5 mM 0.1121 mL 0.5605 mL 1.1210 mL
10 mM 0.0560 mL 0.2802 mL 0.5605 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 5 mg/mL (2.80 mM); Clear solution

    此方案可获得 ≥ 5 mg/mL (2.80 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

暂无相关参考文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度 mg/ml;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。